ArticleActa psychiatrica Scandinavica2026
Transcranial Magnetic Stimulation Retreatment for Recurrent Depression: A Large Real-World Multisite Cohort Study.
Article in Acta psychiatrica Scandinavica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
introductionWhen depressive symptoms return after an initial response to transcranial magnetic stimulation (TMS), evidence to guide use of a second acute course is strikingly limited. We aimed to estimate how often and how quickly patients with recurrent major depressive disorder benefit from a second course of transcranial magnetic stimulation after they previously improved with TMS.
methodsA retrospective cohort study across 20 outpatient centres included 259 patients who received ≥ 2 TMS courses between January 1, 2023 and October 1, 2025, and had clinically significant depressive symptoms at the start of course 2; 177 prior responders formed the primary cohort. Treatment used standard 10-Hz left dorsolateral prefrontal cortex TMS. Response and remission were assessed using the PHQ-9 and/or BDI-II; response was defined as a ≥ 50% reduction and remission as PHQ-9 ≤ 4 and/or BDI-II ≤ 9. Symptom change from baseline to end of course 2 and time to first response by session were compared between courses.
resultsAmong past responders, 146 of 177 patients (82.5%; 95% CI, 76.1%-87.8%) responded again during course 2 and 96 of 177 (54.2%; 95% CI, 46.6%-61.7%) achieved remission. PHQ-9 scores decreased by a median of 65.0% (p < 0.001), and BDI-II scores decreased by a mean of 12.0 points (95% CI, -14.0 to -10.0; p < 0.001). Among responders, the first session meeting response criteria occurred earlier during retreatment than during the initial course on both PHQ-9 (median session, 12 vs. 16; hazard ratio = 1.40, 95% CI, 1.14-1.72; p = 0.001) and BDI-II (13.5 vs. 22.5; hazard ratio = 1.46, 95% CI, 1.07-2.00; p = 0.018).
conclusionsMost patients who previously benefited from acute TMS improved again when symptoms recurred, and among responders, the first session meeting response criteria often occurred earlier during retreatment than during the initial course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.